PTC THERAPEUTICS, INC.

0001070081 false 0001070081 2026-06-08 2026-06-08 ​ ​ UNITED STATES ​ SECURITIES AND EXCHANGE COMMISSION ​ WASHINGTON, D.C. 20549 ​ FORM 8-K ​ CURRENT REPORT ​ Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ​ Date of Report (Date of earliest event reported): June 8, 2026 ​ PTC THERAPEUTICS, INC. ​ (Exact Name of Company as Specified in Charter) ​ ​ ​ ​ ​ ​ Delaware ​ ​ ​ 001-35969 ​ ​ ​ 04-3416587 (State or Other Jurisdiction ​ (Commission ​ (IRS Employer of Incorporation) ​ File Number) ​ Identification No.) ​ ​ ​ ​ ​ ​ 500 Warren Corporate Center Drive ​ ​ ​ ​ ​ Warren , NJ ​ ​ 07059 (Address of Principal Executive Offices) ​ ​ (Zip Code) ​ Registrant’s telephone number, including area code: ( 908 ) 222-7000 ​ Not applicable (Former Name or Former Address, if Changed Since Last Report) ​ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below): ​ ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ​ ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ​ ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ​ ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ​ Securities registered pursuant to Section 12(b) of the Act: ​ ​ ​ ​ ​ ​ Title of each class ​ ​ ​ Trading Symbol(s) ​ ​ ​ Name of each exchange on which registered Common Stock, $0.001 par value per share ​ PTCT ​ Nasdaq Global Select Market ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ​ Emerging growth company ☐ ​ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​ ​ ​ ​ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 8, 2026, Alethia Young, a member of the board of directors (the “Board”) of PTC Therapeutics, Inc. (the “Company”), notified the Company of her resignation from the Board effective June 8, 2026. Ms. Young has informed the Company that her decision is based on her need to focus on commitments to her other work activities and was not due to any disagreement with the Company. The Company and Ms. Young entered into a consulting agreement effective as of June 8, 2026 (the “Consulting Agreement”) pursuant to which Ms. Young will remain as an advisor to the Company, with a term continuing through June 8, 2027. Pursuant to the Consulting Agreement, Ms. Young will receive a monthly consulting fee of $4,166.67. The foregoing description of the Consulting Agreement is qualified in its entirety by reference to the full text of the Consulting Agreement, a copy of which is attached hereto as Exhibit 10.1 and incorporated herein by reference. Item 9.01. Financial Statements and Exhibits. (d) Exhibits ​ ​ ​ Exhibit No. ​ ​ ​ Description 10.1 ​ C onsulting Services Agreement between the Registrant and Alethia Young 104 ​ The cover page from this Current Report on Form 8-K, formatted in Inline XBRL ​ ​ ​ ​ SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. ​ ​ ​ ​ PTC Therapeutics, Inc. ​ ​ Date: June 9, 2026 By: /s/ Pierre Gravier ​ Name: Pierre Gravier ​ Title: Chief Financial Officer ​ ​